Prevention of chemotherapy-induced nausea and vomiting: Belgian antiemetic treatment options anno 2018

BJMO - volume 12, issue 2, march 2018

W. Lybaert MD, P. Clement MD, PhD, K. Punie MD, J. Mebis MD, M. Renard , H. Wildiers MD, PhD


Chemotherapy-induced nausea and vomiting remains an important adverse effect of treatment in daily clinical practice. Recently, new data on combinations of antiemetic agents became available for the prevention of acute and delayed nausea/vomiting in patients receiving highly and moderately emetogenic chemotherapy. As a result, the leading international cancer societies updated their antiemesis guidelines. This text aims at providing guidance regarding these new regimens in the prophylaxis of chemotherapy-induced nausea and vomiting, with a particular focus on highly emetogenic chemotherapy.

(BELG J MED ONCOL 2018;12(2):51–60)

Read more

Immune checkpoint inhibition in triple negative breast cancer: targeting Achilles’ heel?

BJMO - volume 12, issue 9, february 2018

V. Geldhof , K. Punie MD, H. Wildiers MD, PhD

Triple negative breast cancers pose an important challenge both for patients and their clinicians due to their aggressive disease course, poor long-term survival and lack of effective systemic treatment options. Recent scientific advances show that the adaptive immune system harbors the intrinsic capacity to eradicate cancer, generally through mechanisms that involve cytotoxic T-cells. Immune checkpoint inhibition boosts the host-anti-tumor response in many solid tumors, including breast cancer. However, cancer cells acquire ways to evade immunosurveillance and intra-tumoral T-cells are often functionally impaired, resulting in overt clinical cancer. Interestingly, the efficacy of immune checkpoint inhibition appears to correlate with tumor immunogenicity and the tumor mutational burden. Triple negative breast cancer has the highest tumor mutational burden of all breast cancer subtypes and therefore is believed to be the most immunogenic subtype. For this reason, clinical trials to date mainly focus on this specific subtype. Here, we review the accumulating evidence for immune checkpoint blockade in triple negative breast cancer.

Read more


BJMO - 12, issue 3, february 2018

L. Jongen , Giuseppe Floris , D. Lambrechts PhD, Annouschka Laenen , Patrick Neven , Grace Mann , Richard Cutler Jr. , A. Lalani , H. Wildiers MD, PhD

Read more

Quality management for systemic treatment of breast cancer

BJMO - volume 12, issue 1, february 2018

D. Verhoeven MD, PhD, F.P. Duhoux MD, PhD, E. de Azambuja MD, PhD, H. Wildiers MD, PhD, P. Vuylsteke MD, A. Barbeaux MD, N. van Damme , E. Van Eycken MD


Limited literature is available about quality management in systemic treatment of breast cancer patients. Professionals are the key players in the identification and interpretation of quality indicators. The Belgian Society of Medical Oncology takes the lead in the field of quality management of systemic treatment for cancer, especially breast cancer. A narrow collaboration with the Belgian Cancer Registry will allow benchmarking. The results will be presented and discussed between peers of the society. This should lead to better outcomes for all Belgian centres. All Belgian Society of Medical Oncology members are called for active participation

(BELG J MED ONCOL 2018;12(1):15–21)

Read more

Systemic chemotherapy regimens in early breast cancer patients: updated recommendations from the BSMO breast cancer task force

BJMO - volume 11, issue 8, december 2017

H. Wildiers MD, PhD, F.P. Duhoux MD, PhD, A. Awada MD, PhD, E. de Azambuja MD, PhD


Since the publication from the Belgian Society of Medical Oncology breast cancer task force in 2014 in the Belgian Journal of Medical Oncology, new information has become available on optimal chemotherapy regimens for early breast cancer patients. On February 24th, 2017, 37 medical oncologists involved in breast cancer management reviewed the most important scientific data on this topic. The authors of this paper summarised the findings, and sent a questionnaire to the members asking for their input. This paper summarises the consensus of this exercise.

(BELG J MED ONCOL 2017;11(8):375–379)

Read more

Highlights in breast cancer

BJMO - volume 11, issue 4, september 2017

Tom Feys MBA, MSc, H. Wildiers MD, PhD

This report will discuss a selection of key studies related to breast cancer discussed during the 2017 annual meeting of the American Society of Clinical Oncology. ASCO 2017 featured important new data generated with CDK4/6 inhibitors in patients with advanced breast cancer and included several abstracts considering the potential of PD-L1 inhibition for breast cancer. In addition to this, updates of several large phase III studies, including MARIANNE, ALLTO and APHINITY were presented. For a more complete overview of breast cancer news presented at ASCO 2017, we refer to the ASCO annual meeting website (

Read more

O.09 Geriatric assessment (GA)- guided interventions in older patients (pts) with cancer

BJMO - 2017, issue 3, february 2017

L. Decoster MD, PhD, C. Kenis PhD, J. Flamaing , P.R. Debruyne , I. De Groof , C. Focan MD, PhD, F. Cornélis MD, V. Verschaeve MD, K. Vanoverbeke , Y. Libert , S. Luce , N. Nols , H. van den Bulck , J.C. Goeminne MD, K. Geboers , J.P. Lobelle , M. Lycke , K. Milisen PhD, H. Wildiers MD, PhD, A. Baitar

Read more